GLP1R and hepatocellular carcinoma: A recently published cohort study was the first to compare GLP-1 receptor agonists vs. long-acting insulin therapy in patients with type 2 diabetes mellitus, demonstrating a lower risk of cirrhosis and HCC in the GLP1 receptor agonist group [100].